"I know that I know nothing","The only thing I know, is that I know nothing"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Precisely
What was the buys and sell? Could most of the run just been bought and barely sells today?
Thank you for this. Will get that done. I recently pounced on a certain company decided to make stock debut after years of being quiet. Took a small amount of money and it boomed. While, I am no savant, I do want to start getting into this a little more. Anyway, thanks for the tidbit. Will do that so I can make my trades.
I totally agree. That doesn't just suddenly have a ridiculous power hour like that. No way.
Do not get me tittilated! Haha
Currently I have $2000 in limbo waiting to settle. So I can't buy some extra shares yet. It's frustrating.
I agree without a doubt. It comes down to people buying shares. The company needs eyes. The best way for this is news.
From the movement at the end of the day, it's clear we will open in the green. I think we will open pretty up tomorrow no problem. Momentum will carry us. Hopefully, the news hits as well. But I rather that hit Tuesday.
That is good to know. I haven't run into issues with Schwab as of yet. But there is always that first time. Plus, I don't trade penny often. But do it from time to time.
Question. Have you thought about opening another account with another company strictly for penny stocks. I use Schwab.
It could be that correction is over and this is the steady state here. I think we could start off negative and finish positive tomorrow
Nice use of the word 'butthurt!' I agree. We want best for both companies. Whatever happens, happens.
Thanks Stewy! If this goes the distance, this will be seared into my brain. Thanks
It does that. Very rarely will it show numbers under a penny unless you look directly at the stock itself.
So you are around what I think. That's what the graphs and charts seem to show when it really started to run.
Sorry meant .60$ not .60%
Just looking at the graph from the past month, it looks to me that we may need to correct another %.60 before we bottom out. IMO
Yeah man. I cant believe I got the shares in time. Made this worth while.
.0085
I lied, this is going way past .008 with this momentum.
It's going to hit .008. Its got too much momentum.
ANDI!!....................... Is my new girlfriend haha
I love this. I was able to purchase another 300K shares before this run. So lucky.
Funny, I took a look at that yesterday. Nice and relaxed and ready to take over the world.
Has anyone heard of the recent CanniMed-Fagron NV distribution deal? Posted yesterday?
CanniMed Therapeutics Inc. Announces Strategic International Cannabis Distribution Agreement with Fagron NV
Fagron to utilize its existing international distribution network to market and distribute CanniMed medicinal cannabis products to 17 specified countries with aggregate population of over 760 million
Primary initial focus on Germany
Germany fully legalized medicinal cannabis in March 2017
Germany’s ~22,000 pharmacies serve a population of over 82 million
Demand for medicinal cannabis in Germany outstrips supply
January 10, 2018 07:00 AM Eastern Standard Time
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) is pleased to announce that it has entered into a global marketing and distribution agreement (the “Agreement”) with the leading global pharmaceutical compounding company Fagron NV of Rotterdam, The Netherlands (Euronext Brussels: FAGR and Euronext Amsterdam: FAGR). Under the Agreement, Fagron and CanniMed will work closely together in utilizing Fagron’s extensive infrastructure to supply CanniMed’s medicinal cannabis products in Germany and other specified countries. Pursuant to the terms of the Agreement, CanniMed is working to supplement its Canadian GMP compliant status with GMP certification in Europe for its cannabis products, which it anticipates will be achieved in Q2 2018. Fagron and CanniMed anticipate first product sales into Germany will commence in Q3 2018, subject to obtaining required export permits.
Pursuant to the Agreement, CanniMed is Fagron’s supplier of cannabis products in the specified countries and the two companies will commit resources to develop and execute a combined marketing and distribution strategy to establish CanniMed as a strong brand in these countries.
“Fagron is perfectly positioned in the highly attractive German market as well as several other countries to drive the penetration of our pharmaceutical grade cannabis products. Our first primary target market, Germany, is particularly exciting as it has legalized medicinal cannabis for distribution through pharmacies and with a population of over 82 million which is more than double that of Canada” said Brent Zettl, President and CEO, CanniMed. “Fagron brings the connections, experience and market credibility to be a highly impactful partner for us internationally. We anticipate that the majority of medicinal cannabis products demanded in these countries will be oils and oil derivate products such as capsules, sublingual wafers and topical creams. The first 12 million 60 ml bottles phase of our 50 million bottles per year oils plant will be coming onstream in late 2018 and will be the foundation for meeting escalating international and domestic medicinal oils demand.”
Rafael Padilla, CEO of Fagron stated “We are very pleased to be working with an industry-leading company such as CanniMed and we believe the German market is a prime target for CanniMed’s highly respected cannabis products, driven by widespread acceptance in Germany of the many medicinal benefits of cannabis. We believe CanniMed has the opportunity to become a long-term major medicinal brand in Germany, where demand for medicinal cannabis products exceeds supply. We are confident that our depth of cannabis and pharmaceutical experience together with our established marketing infrastructure and connections in Germany and other countries combined with CanniMed’s leading expertise and products will be very effective in achieving international market penetration of CanniMed’s products.”
About CanniMed Therapeutics Inc.
CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.
CanniMed, through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical cannabis system for 13 years, and has been producing safe and consistent medical cannabis for thousands of Canadian patients, with no incident of product diversion or recalls.
For more information, please visit our websites: www.cannimed.ca (patients) and www.cannimedtherapeutics.com (investors).
About Fagron NV
Fagron NV, located in Waregem, Belgium and with operational head office in Rotterdam, The Netherlands, is publicly listed (FAGR) on Euronext in Brussels, Belgium and Amsterdam, The Netherlands. Fagron has over 2,000 employees and is active in 34 countries around the world, with a focus on the core regions Europe, South America and the United States. Fagron is a leading global pharmaceutical compounding company, bringing personalized pharmaceutical care to hospitals, pharmacies, clinics and patients.
In Germany, Fagron’s extensive infrastructure is connected into the country’s approximately 22,000 pharmacies, where it is active in distributing a wide range of pharmaceutical products.
For the year ended December 31, 2016 Fagron reported global revenue of €422 million ($CAN633 million) and EBITDA of €87 million ($CAN130 million).
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanniMed to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
These forward-looking statements include, but are not limited to, statements relating to our expectations with respect to: anticipated product sales revenue by CanniMed and first product sales in Q3 2018. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. In respect of the forward-looking statements and information concerning the Agreement and its anticipated benefits. CanniMed has provided such statements and information in reliance on certain assumptions that it believes are reasonable at this time, including assumptions as to the ability of CanniMed to obtain all required permits and approvals for sales to Germany. There can be no assurance that the revenue to be generated from product sales will not be adversely affected by production or supply delays and changes in market prices. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks including delays in permitting and production. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on other factors that could affect the operations of CanniMed are included in documents on file with applicable securities regulatory authorities, including the Annual Information Form of CanniMed dated December 8, 2017, available on sedar.com.
The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. CanniMed does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
Neither the Toronto Stock Exchange or its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contacts
CanniMed Therapeutics Inc.
Media
Dara Willis, 416-836-9272
dhw@cannimed.com
or
Investor Relations
invest@cannimed.com
Shoot, I forgot it was 28 grams. That's a ton. My fault.
Just doing some quick math here. And someone who knows more about the market than me. Would it be safe to assume roughly 3-4% of the worlds population probably will be smoking Marijuana. And the average sale per month be around an ounce? Because with numbers like that we are looking at close to a $500 bill market. Do think that is out of the question?
I want to buy more of this stock, but am afraid to remove then have to wait until funds settle. Also, this stock could just turn up and I get screwed. I might just hold my shares now. This stock is going to come back. I am not worried about the company at all. Just getting a little more shares haha
You are most likely correct, I was throwing out what I thought could be a possibility.
I really hope this holds so I can purchase more when my funds clear.
It's not really lies and deceit when there are multiple sources stating the inner workings of what is going on. Its pretty clear some major investors see the company not in the right position, and especially do not see any haste for expansion from the CEO. It's one thing if it is one source, but sources like Vice are a big deal. So....
Not sure what they are trying to do anyway. These deals are in place and the complexes are on their way. They are hurting themselves if anyone. Their play makes no sense.
I mean, we should be able to try the product. Or they just bake the entire complex where we are in. Hit us with Marijuana. haha
I will give you a 3 out of 10 for your ability to properly troll.
That is correct. You are talking about aeration, nitrates, temperature and humidity control, proper sunlight, water. No joke man. It's nonstop work
I remember you guys posting that, but thought I would share the article that specifically states what shareholders are saying what. If this one shareholder who has been there from day one says he is voting 'yes', he definitely isn't the only one. He see massive value. God only knows what his shares will be when it gets converted to Aurora. He will be sitting nice!
If that doesn't make you feel better this will. It's pretty dead set that we will take over CanniMed. Some of the longest holding stock owners of CanniMed realize that Zettl just isn't cutting the grade. He was pioneer in the sector being the first in the Canadian space, but just hasn't been going anywhere. It's seem that many, if not a majority, of CanniMed shareholders want out. Take their profits and come over to a company making huge moves. They are in favor. Read down below!
https://news.vice.com/en_ca/article/vbyygy/these-cannimed-shareholders-want-aurora-to-buy-out-their-company
Right. Lots of cost will go into temperature and climate control that is for sure!
Exactly. And right! Well, if it makes money and helps create jobs, and brings down the debt (questionable).. I think the right would easily use this as a win for them. I think their heart could change with an easy gust of wind. The majority of the country wants to legalize it, both Rep and Dem, so not sure why this couldn't be a bipartisan showing. I think it would look good for him regardless of how he went about it. IMO
Anyway, we will see. If it does, this company will just go crazy $ACBFF
Correct! It's just a matter of time to which the CEO gives in and the deal is struck, until then, he is going to sit and hold on for dear life... for what reason I have no clue.